Targeted gene therapy for hard-to-treat retinoblastoma
Part of Cancer, Eyes & vision clinical trials.
This trial tests an experimental drug that targets a specific gene (NUDT21) to treat retinoblastoma that has not responded to standard treatments. It is for children who have active tumor in only one eye and whose only other option is to remove the eye, but who want to try to save the eye instead.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active retinoblastoma tumor in only one eye (the other eye is either already removed or has no tumor).
- Standard treatments (like chemotherapy or radiation) have not worked or the tumor has come back, and your doctor says removing the eye is the only option left, but you want to try to save the eye.
- Your child must be older than 6 months at the start of the study.
- Your child's kidneys and liver must be working normally (blood tests will check this).
- You must not have any infections, uncontrolled seizures, heart problems, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
This trial studies whether newer “save-the-eye” treatment plans can control retinoblastoma (eye cancer) while keeping vision as good as possible. It compares different conservative treatment strategies depending on how the tumor looks and where it is.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
This Phase 2 study tests a way to deliver cancer treatment directly inside the eye to treat retinoblastoma. It may help shrink the tumor while limiting treatment to the eye when possible.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
Hear when a new Retinoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.